MACROLIDE TREATMENT FOR “CHLAMYDIAL ASTHMA”: EVIDENCE FOR ENROLLMENT BIAS IN AN EFFECTIVENESS TRIAL
http://clinicaltrials.gov/show/NCT00266851

David Hahn1,2,4, Mike Grasmick1,2, Scott Hetzel3

1Wisconsin Research and Education Network (WREN), 2Departments of Family Medicine and Biostatistics, University of Wisconsin School of Medicine and Public Health, 4Dean Medical Center, Madison, Wisconsin

Context: Increasingly robust in vitro, animal model, epidemiological and clinical evidence supports macrolide treatment for chlamydia-associated asthma, characterized by increased severity, steroid resistance, concomitant chronic bronchitis and/or COPD (i.e., the “overlap syndromes” that have been systematically excluded from US asthma treatment trials). Another challenge when performing effectiveness randomized clinical trials (RCTs) for “chlamydial asthma” is off-study treatment sought by severely affected patients. Objectives: To assess the impact of off-study macrolide treatment on the generalizability of RCT results. Design: RCT with an open-label (OL) arm for eligible subjects who declined randomization. Setting: Primary care practices throughout North America. Patients: 96 adults with persistent asthma and reversible airway obstruction, of whom 22 (23%) elected the OL arm. Intervention: Azithromycin (600 mg) or placebo, daily for 3 days, then once weekly for 11 weeks as an adjunct to usual care. Outcomes were assessed until 48 weeks post-randomization. Main and Secondary Outcome Measures: Main: asthma symptoms. Secondary: asthma quality of life (AQLQ) and asthma control (ACQ). Results: Baseline: compared to randomized subjects (n=74), OL subjects (n=22) reported greater asthma severity (P=0.03), higher frequency of asthma initiation after an acute lower respiratory tract illness (P=0.04) and more chronic sinusitis (P<0.001). Most OL subjects also reported temporary asthma remission after prior conventional azithromycin treatment for unrelated illnesses. Outcomes: there were few significant differences for any outcome between subjects randomized to azithromycin or placebo (RCT groups). Compared to the RCT groups at 6 months after treatment completion, OL subjects demonstrated persistent clinically and statistically significant improvements in symptoms (P=0.001), AQLQ (P=0.003) and ACQ (P=0.005). Conclusions: Compared to randomized subjects, the OL group had more severe disease and a greater likelihood of long-lasting treatment benefit. Future asthma macrolide effectiveness RCTs should focus on more severe asthma, and should include an open-label arm as an external validity control to mitigate the risk of “enrollment bias.”